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Cannabinoids Suppress Dendritic Cell-Induced T Helper Cell Polarization
Tangying (Lily) Lu

ABSTRACT

Cannabinoids suppress Th1 immunity in a variety of models including
infection with the intracellular pathogen Legionella pneumophila (Lp). To
examine the cellular mechanism of this effect, mouse bone marrow-derived
dendritic cells (DCs) were studied following infection and drug treatment. DCs
produced high levels of IL-12p40 following Lp infection. THC suppressed this
cytokine response in a concentration-dependent manner and the
endocannabinoids 2-arachidonoyolglycerol and virodhamine less potently
suppressed cytokine production. DCs expressed mRNA for cannabinoid
receptor 1 (CB1), CB2, and transient receptor potential vanilloid type 1 (TRPV1);
furthermore, inhibition of Gi signaling by adding pertussis toxin completely
attenuated the suppression induced by low concentrations of THC but not at high
concentrations. In addition, the THC suppression was partially attenuated in DC
cultures from CB1 and CB2 knockout mice and in cultures from normal mice cotreated with THC and cannabinoid receptor antagonists. Cytokine suppression
was not attenuated by pretreatment with the TRPV1 antagonist capsazepine,
viii

suggesting that Gi signaling and cannabinoid receptors, but not TRPV1, are
involved in THC-induced suppression of DC potential to polarize the
development of naïve T cells to be Th1 cells. Besides IL-12, THC suppressed
other DC polarizing characteristics such as the expression of MHC class II and
co-stimulatory molecules CD86 and CD40, as well as the Notch ligand Delta 4.
However, THC treatment did not affect other DC functions such as intracellular
killing of Lp and Lp-induced apoptosis. Testing the capacity of THC to suppress
DC polarizing function with T cells showed that DCs infected in vitro with Lp were
able to immunize mice when injected prior to a lethal Lp infection; however, the
immunization potential along with Th1 cytokine production was attenuated by
THC treatment of the cells at the time of in vitro infection. In addition, THCtreated and Lp-infected DCs poorly stimulated primed splenic CD4 T cells in
culture to produce IFN-gamma (IFN-γ); however, this stimulating deficiency was
reversed by adding recombinant IL-12p40 protein to the cultures.

In conclusion,

the data suggest that THC inhibits Th1 polarization by targeting essential DC
functions such as IL-12p40 secretion and the maturation and expression of costimulatory and polarizing molecules.

ix

INTRODUCTION

Cannabis products and cannabinoids

Cannabis is one of the oldest psychotropic drugs known in human history
and has been used from the earliest records. In 2737 BC, Shen Nung, an
emperor of ancient China, had described the properties and therapeutic uses of
cannabis in his compendium of Chinese medicinal compounds (98). Two main
preparations derived from cannabis are marijuana and hashish. Marijuana is a
green, brown, or gray mixture of dried leaves, stems, seeds, and flowers of the
hemp plant (cannabis sativa) while hashish is the viscous resin of the Indian
hemp plant (97). Despite the fact that cannabis and its products have been
widely noted for their effects as an analgesic, appetite stimulant, antiemetic,
muscle relaxant and anticonvulsant for centuries (178), it was not until the 1940s
that scientists were able to purify and define the structures of the cannabis plant,
including more than 60 dibenzpyrene components known as cannabinoids. The
major psychoactive ingredient of cannabis is delta-9-tetrahydrocannabinol,
usually termed as THC. Other cannabinoids in cannabis such as delta-8tetrahydrocannabinol (Δ8THC), cannabinol (CBN), cannabidiol (CBD),
cannabicyclol (CBL), cannabichromene (CBC) and cannabigerol (CBG) are
1

present in small quantities and have little psychoactive effects compared to THC
(14); however, it has been suggested they may have synergistic effects in
combination with THC (8).

Cannabinoid receptors

Cannabinoids usually exert their actions by binding to specific receptors
and two types of cannabinoid receptor have been decribed to date. These
receptors are found in mammals, birds, fish, and reptiles (49). Cannabinoid
receptor type 1 (CB1), originally cloned by Matsuda et al. in 1990 from a rat brain
cDNA library by a probe derived from the sequence of bovine substance-K
receptor, exhibits 97 to 99% amino acid sequence identity across species (30,
57, 114, 115). CB1 has been demonstrated in high levels in the central nervous
system (CNS) and is predominantly found presynaptically expressed, and
associated with the behavioral effects following cannabinoid usage, such as loss
of short-term memory, dizziness, ataxia and sedation (34). Peripheral
expression of CB1 has also been found in many peripheral tissues including
heart, vascular endothelium, small intestine, liver (144, 176) and in the cells of
immune system such as splenocytes (78, 136), mast cells (163) and DCs (43,
113). Cannabinoid receptor type 2 (CB2) cloned in 1993 by Munro and
associates from a human HL60 promyelocytic cell line library, exhibits 48%
homology with CB1 (129). CB2 expression differs from CB1 in that it is relatively
undetectable in the CNS (129, 164) except for microglia that express both CB2
2

and CB1 (54, 183) (26). CB2 is expressed in a high level in the tissues of
lymphoid system including the thymus, tonsils, bone marrow and spleen (56, 87,
105). Both receptors are coupled to Gi proteins to negatively regulate adenylyl
cyclase and cAMP accumulation. This Gi protein-induced signal can be blocked
by pertussis toxin (71).

Endocannabinoids and synthesized cannabinoids

Discovery of the cannabinoid receptors in humans and animals led first to
the prediction and later to the actual findings of endogenous ligands termed
endocannabinoids. Anandamide (Arachidonoylethanolamide; AEA) (40) and 2arachidonylglycerol (2-AG) (119), both derivatives of arachidonic acid, are the
most studied endocannabinoids. These endocannabinoids participate in the
regulation of neurotransmission (10, 41, 69) and many biological effects
associated with marijuana connabinoids. 2-AG is a full and potent agonist for
both CB1 and CB2, while AEA is more selective to CB1 than to CB2 (70). AEA
has also been shown to bind vanilloid receptors that are heat-gated, cation
channels, sensitive to the vanilloid compound capsaicin and its analogues (196).
Many studies have shown that upon stimulation with agents such bacteriaderived lipopolysaccharide (LPS), immune cells, including macrophages (42),
DCs (113) and peripheral-blood mononuclear cells (PBMCs) (107) release the
endocannabinoids 2-AG and AEA that may act as chemotactants for leukocytes
and take part in immune regulation (83). A novel endocannabinoid, Virodhamine,
3

also a derivative of arachidonic acid, has been described recently as an agonist
acting on both CB1 and CB2. Virodhamine was shown to be highly produced in
spleen tissues suggesting its potential role in immunomodulation (148). Other
endogenous cannabinoids including N-arachidonyldopamine (NADA) and
Docosatetraenylethanolamide (DEA) have also been described. NADA is
produced in mammalian nervous tissue and acts at vanilloid and cannabinoid
receptors with more selectivity toward CB1 than CB2 (16, 36, 73). DEA is an
endogenous ligand selectively activating CB1, and produced by astrocytes. It
acts as a cannabimimetic in vivo, causing hypothermia, analgesia, motor activity
inhibition and catalepsy (12, 61).
In addition to these naturally occurring cannabinoids and
endocannabinoids, also many structural analogues of cannabinoids have been
synthesized in a number of laboratories. Some of these analogues include
arachidonyl-2-chloroethylamide (ACAE), ajulemic acid (AJA), methyl arachidonyl
fluorophosphonate (MAFP), JWH-133 and CP55, 940. Among these analogues,
ACEA has high selectivity for CB1 (64, 70). AJA is a nonpsychoactive, synthetic
analog of a metabolite of THC with relatively low affinity for cannabinoid
receptors but some demonstrated efficacy in animal models of chronic pain (46)
and inflammatory diseases (24). MAFP is a potent, irreversible inhibitor of AEA
amidase, the enzyme responsible for AEA hydrolysis, and a selective ligand for
CB1 (39, 110). JWH-133 is a highly selective agonist for CB2 while CP55, 940
has high affinity for both CB1 and CB2 (71). Some of these analogues of
cannabinoids possess low CB1 binding resulting in low psychoactivity. Therefore,
4

these analogues may have potential therapeutic usage in immune inflammatory
diseases associated with dysregulation of cannabinoid receptor signaling.

Receptors involved in cannabinoid effects

Since both CB1 and CB2 are Gi protein-coupled receptors, the signaling
mechanisms involved in cannabinoid effects are associated with activation of Gi
proteins. It is well known that these heterotrimeric proteins are activated by
ligand binding to a seven-transmembrane G protein-coupled receptor (GPCR)
causing a conformational change, promoting an exchange of GDP for GTP by
the Gα subunit, and the dissociation of Gα from the Gβγ dimmer. Activated Gα and
Gβγ subunits subsequently modulate specific downstream signaling pathways,
and therefore relay information intracellularly in response to various extracellular
receptor stimulants (117). Dysregulated G-protein signaling leads to pathologies
in numerous organ systems and many important classes of medications can
modify GPCR signaling pathways either directly or indirectly (155). A number of
studies suggested that Gi signaling was involved in cannabinoid effects mainly
through binding to either CB1 or CB2 (69). However, although currently there are
only two known cannabinoid receptors, other known or yet to be identified
receptors or non-receptor mediated mechanisms may be involved in cannabinoid
effects. For example, the synthetic cannabinoid AJA, which has potent antiinflammatory effects but low affinity to CB2, is known to bind directly to and
activate the peroxisome proliferator-activated receptor gamma (PPAR-gamma), a
5

pharmacologically important member of the nuclear receptor superfamily (24,
101). Similarly, the plant-derived cannabinoid CBD has immunosuppressive
effects and binds weakly to both CB1 and CB2. One recent study demonstrated
that the CBD effect could be reversed by an A2a adenosine receptor antagonist
and abolished in A2a receptor knockout mice providing a non-cannabinoid
receptor mechanism mediated by cannabinoids (27). Also, it has been shown
that the endocannabinoid AEA can activate TRPV1 receptors (102, 108).
However, some cannabinoid effects seemed to be mediated by non- CB1, nonCB2 and non-TRPV1 receptor mechanisms that remain to be elucidated (65, 124,
143). Overall, the signaling pathway involved in cannabinoids is more diverse
than originally speculated and some effects are not mediated by the already
known cannabinoid receptors.

Effects of cannabinoids on innate immunity

Innate immunity is critical in immune surveillance against pathological
infection agents (188). Macrophages and neutrophils are mediators of innate
immunity and can recognize, phagocytize and kill microbes through the activation
of several enzymes including oxidases and inducible nitric oxide synthase
(iNOS); these enzymes produce the toxic reactive oxygen intermediates (ROI)
and nitric oxide (NO) that not only kill microbes but cause inflammation and
tissue damage (162). It has been shown that THC, through inhibition of cAMP
signaling, inhibits iNOS and NO production by macrophages stimulated with LPS
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(77). In similar studies, lung alveolar macrophages collected from marijuana
smokers exhibited limited antimicrobial activity. However, treatment with
granulocyte/macrophage colony-stimulating factor (GM-CSF) or IFN-γ restored
these cells to produce NO and antibacterial efficiency (159, 165). In addition, the
endogenous cannabinoid AEA has been shown to suppress, though not as
strong as THC, the expression of cytokines such as IL-1, IL-6 and TNFα by rat
microglial cells, the macrophage cell type in brain (149). Gongora et al. recently
showed that synthetic cannabinoid CP55, 940 blocked the expression of MHC
class II molecules induced by IFN-γ on the surface of microglial cells (58). Also
CP55, 940, but not AEA treatment, inhibited superoxide production in neutrophils
(94), while macrophage proteolytic and lysosome processing could be
suppressed by THC (116). It was recently reported that JWH-133 inhibited the
production of IL-12p40 and enhanced IL-10 by LPS- or Theiler's virus -activated
macrophages (32). In addition, it has been demonstrated that the main
nonpsychoactive component of marijuana cannabidiol (CBD) significantly
modulated murine macrophage cytokine production and chemotaxis (160).
Natural killer (NK) cells, which are a class of innate immune cells, can
rapidly respond to intracellular infections with viruses or bacteria by direct killing
of the infected cells (60). It has been shown that THC can suppress NK cell
function in both animal models (85, 142) and humans (169). A recent study
using marijuana users demonstrated that cannabis induced a significant
decrease in the absolute number of NK cells as well as T and B cells in
peripheral blood (48). In other studies, CB1 and CB2 antagonists were shown to
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partially reverse the THC- inhibited NK cytolytic activity in mice (111). In
addition, the endogenous cannabinoid 2-AG, but not AEA, has been shown to
induce the migration of KHYG-1 cells, an NK leukemia cell line, and human
peripheral blood NK cells (82). These studies demonstrated that various
cannabinoids are capable to significantly modulate (mostly suppress) the innate
immune cell functions which include migration, phagocytosis and processing
foreign pathogens, cytokine production, and killing of target cells. Innate
immunity can also highly impact the development of adaptive immunity.
Therefore cannabinoid modulation of innate immune cells might also modulate
the activation and development of T cells and B cells.

Effects of cannabinoids on adaptive immunity

T helper cells (Th) are CD4+ T cells that through a variety of mechanisms
provide help for activating adaptive immunity. Th cells generate their effects by
releasing cytokines and/or by direct cell-cell interactions. T helper cytokines and
co-stimulatory molecules interact with macrophages, B cells and CD8+ killer cells
to produce the effector mechanisms of adaptive immunity such as activated
macrophages, antibodies and killer T cells to clear the invading pathogens (137).
Based on the types of cytokines Th cells produce, they are classified into two
subtypes, i.e., T helper cell type 1 (Th1) and type 2 (Th2). Th1 cells produce IL2, IFN-γ and TNF-β, which promote the development of cell-mediated immunity,
while Th2 cells produce IL-4, IL-5, IL-10 and IL-13, and can activate humoral
8

immunity, mainly directed against extracellular infections (4, 45). Recent studies
show that many immune disorders are attributable to the collapse of the system
controlling the proportion of Th1 and Th2 cells. For example, allergy, multiple
sclerosis, and organ-specific autoimmune disease have pathology associated
with aberrant Th1 and Th2 polarization (92, 100, 128). Moreover, restoration of
the proper balance between Th1 and Th2 cells is generally considered essential
in the treatment of tumors, which are generated when cellular immunity is
affected by immunosuppressive factors (93).
Marijuana smoking increases susceptibility to infections (84) and is a risk
factor in cancers of the respiratory system (174). Many studies indicate that
cannabinoids have a Th biasing effect that shifts Th1 to Th2 response. Our
group previously examined the effect of THC on host immune resistance to
infection with Legionella pneumophila (Lp) (89, 134). Lp is a facultative, Gramnegative, intracellular bacterial pathogen that causes Legionnaires’ disease in
healthy as well as especially immunocompromised individuals (55). Host
resistance to this pathogen depends on activation of Th1 cells, cell-mediated
immunity, and acute phase cytokine mobilization (17, 133, 175), and THC was
shown to suppress Th1 immunity and concomitantly to enhance Th2
development that could not mediate the protection against Lp infection (89, 134).
These studies suggested that cannabinoids may have the unique character of
biasing immune responses away from Th1 and toward Th2. The mechanism of
the T helper biasing effect is unclear, but in mice involves activation of
cannabinoid receptors, suppression of serum interleukin-12 (IL-12) and splenic
9

IL-12 receptor expression, suppression of serum interferon γ (IFN-γ) (89), and an
increase in the Th2 biasing transcription factor GATA3 (86).
Also the effect of THC on Th basing has been observed in other animal
models. Zhu et al. demonstrated THC decreased the production of Th1 cytokine
IFN-γ and increased the immunosuppressive cytokines IL-10 and TGF-β,
disrupted host anti-tumor immunity and promoted lung tumor growth (192).
Similarly, a recent paper by Mckallip et al. demonstrated THC enhanced breast
cancer growth and metastasis along with increased Th2 but decreased Th1
related gene expression (118). It was not clear in this study if the suppression of
cytokines was due to the enhanced Th2 response or the activation of T
regulatory cells, which are characterized as CD4+CD25+Foxp3+ and able to
produce IL-10 and TGF-β (146). The alteration effect of THC on the balance of
Th1 and Th2 cytokines was also observed in human T cell cultures stimulated
with allogeneic DCs (191) and in peripheral blood mononuclear cells (PBMCs)
isolated from marijuana smokers (140). Therefore, it has been implicated that
cannabinoids have T helper biasing effect. However, the precise molecular and
cellular mechanisms for these effects are far from defined; also the involvement
of cannabinoid receptors (CBRs) remains unclear.

Effects of cannabinoids on DCs

DCs are professional antigen-presenting cells (APCs) that are generated
in the bone marrow and migrate as precursor cells to sites of potential entry of
10

pathogens. During the past decade, intensive studies have demonstrated that
DCs are central to the integration of innate and adaptive immunity (11). In
contrast to B and T lymphocytes, DCs express many pattern recognition
receptors including various Toll-like receptors (TLRs) and are therefore uniquely
able to sense stimuli such as bacterial and viral infection as well as tissue
damage and necrosis (47). Immature DCs residing in tissues respond to
antigenic signals in the environment, leading to their maturation and migration to
lymphoid organs. During this process, the phenotypic characteristics and
functions of these cells change, including reduced phagocytic capacity and
increased secretion of high levels of immunostimulatory cytokines such as IL-12
and expression of MHC and co-stimulatory molecules (79). Also, expression of
the polarizing Notch ligands, Jagged and/or Delta, is increased (6). Matured DCs
then acquire the ability to direct the development of adaptive immunity including
shaping the type of Th cell response (79). In addition, it is becoming evident that
DCs also play a critical role in amplifying the innate immune response, either
directly by stimulating NK cells and other innate immune cells (37) or indirectly
through orchestrating Th development. Studies have delineated the role of DCs
in immune responses to a variety of pathogens, including bacteria, viruses, and
protozoan parasites as well as to tumors (13, 126).
Little is known, however, concerning the role of cannabinoids on DCs.
Only recently it has been shown that both CB1 and CB2 receptors are expressed
on human and murine DCs (43, 113); and several endocannabinoids including
AEA and 2-AG were found to be present in lipid extracts from immature DCs
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(113). These findings suggest the possible involvement of DCs in cannabinoid
modulatory effects on immunity including THC induced shift from Th1 to Th2
effect. The current project, therefore, studys the immunomodulatory effect of
cannabinoids on mouse bone marrow-derived DCs during Lp infection.

Project significance

The current study examines a model of infection using Lp infected DCs
which were treated with THC and related pharmacological agents. This study
uncovers detailed mechanisms of the immunomodulatory effects of cannabinoids
on DCs especially during the primary stages of infection and biasing toward T
helper immunity. Moreover, even though a Th shift might be detrimental in the
case of Lp and other intracellular pathogenic infections in mice and human
because Th1 immunity is critical to recovery from these infections, in certain
autoimmune diseases, for example systemic lupus erythematosus (SLE), the
enhanced expression of Th1 immunity to self proteins can be a major cause of
the development of disease (125). In this instance, cannabinoids might have
therapeutic potential by suppressing Th1 immunity. The traditional focus for
immunosuppressive drugs has been on lymphocytes as the primary cellular
target. However, it is now understood that several classical and newly
established immunosuppressive drugs interfere with immune responses in the
early stages by suppressing DC differentiation, maturation and activation (59).
Moreover, DCs have been suggested as immunotherapy for a number of cancers
12

(21, 132) and as adjuvants to induce Th1 and Th2 immunity (81). This study
provides a close examination of cannabinoids on DC biology and clues to the use
of these drugs in the pharmacological manipulation of immune responses.
Overall, the results gathered will better define the public health risk of smoking
marijuana and exposure to other cannabinoid agents as well as provide potential
uses for these agents as immunomodulating and anti-inflammatory therapeutics.
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OBJECTIVES

The studies to be conducted will investigate the impact of cannabinoids on
mouse bone marrow-derived DCs. Previous studies suggested that
cannabinoids bias Th polarization and we believe that cannabinoids influence the
functions of DCs which are key to the polarizing event. Preliminary results from
our laboratory showed that THC treatment of murine bone marrow-derived DCs,
infected with Lp, suppressed the production of IL-12p40 (Figure 1), a key protein
involved in Th1 polarization. These findings led to the hypothesis that
cannabinoids, such as THC, suppress immunity against Lp infection by inhibiting
the Th1 polarization function of DCs. In order to verify this hypothesis, the
following aims are proposed.

Aim 1. To determine the effect of cannabinoids on the polarizing phenotype
of DCs infected with Lp

Evidence is accumulating that endocannabinoids are physiologically
essential molecules in various biological systems including the immune system
(83, 87). However, the specific immunomodulatory effects of cannabinoids on
DCs have not been fully investigated (84). DCs are the major source of IL-12
14

production in the early stages of an infection, and IL-12 is the key cytokine to
direct Th naive cell development to Th1 cells (137). We will study the kinetics of
IL-12p40 production in Lp-infected DC cultures and will determine the effect of
THC treatment on the quantitative and qualitative aspects of IL-12p40
production. Similar experiments will be done using LPS as stimulant. In addition,
we will examine the effect of other cannabinoid receptor agonists on IL-12p40
including the endocannabinoids 2-AG and Virodhamine, as well as CB1-selective
agonists ACEA, AJA, Methanandamide, MAFP, DEA and NADA, and the CB2selective agonist, JWH-133. A variety of DC characteristics in addition to IL12p40 production are known to influence T cell subset development (79).
Therefore, we will also examine the effect of THC on the expression of DC
maturation markers including MHC class II and the co-stimulatory molecules
CD86 and CD40, and the Notch ligand Delta 4 (6). In addition, DC functions
such as Lp intracellular killing ability and Lp induced-apoptosis will also be
studied.

Aim 2. To determine the role of cannabinoid receptors in drug effects on
DC polarization

Both CB1 and CB2 have been reported to be involved in the THC-induced
attenuation of IL-12 production in THC-treated mice infected with Lp (89). We
detected the mRNA expression of both cannabinoid receptors in DCs by using
15

semi-quantitative RT-PCR. CB1 and CB2 are Gi protein-coupled receptors. Gi
signaling is sensitive to pertussis toxin inhibition and has been suggested to be
able to suppress IL-12 production (19, 89). We therefore will examine if the role
of Gi-mediated signaling pathways in the suppression of IL-12p40 by THC in
experiments using the Gi inhibitor, pertussis toxin. Also, experiments will be
performed using CB1-/- mice (194) and CB2-/- (23) mice in combination with
receptor antagonists to fully examine the involvement of cannabinoid receptors.
Moreover, other receptors, such as TRPV1, have also been reported to mediate
cannabinoid effects (180). We, therefore, will examine its role in THC effects on
IL-12p40 production by pretreatment with the TRPV1 antagonist capsazepine. In
addition, the intracellular activation of MAP kinases has been shown to regulate
IL-12 production (18, 179, 186); by using specific antagonists MAP kinase
involvement in Lp induced IL-12p40 and suppression byTHC will be studied.

Aim 3. To determine the effect of THC treatment on the T helper polarizing
function of DCs

Effective protection from infections with intracellular microorganisms
needs the induction of cell-mediated immune responses requiring the activation
of Th1 cells stimulated by the interaction between naïve T cells and polarized
DCs (123). To examine the mechanism of the effect of THC on the polarizing
function of DCs with antigen (Ag)-specific T cells, Lp-infected DCs will be treated
with THC and then co-cultured with Lp-primed splenic CD4+ T cells to detect the
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protein levels of IFN-γ and IL-12p40 in supernatants. Furthermore, we will
examine the immunization effect of Lp-infected DCs treated in culture with either
DMSO or THC to induce protective immunity in mice when injected prior to Lp.
In these experiments, mice mortality will be monitored and Th1 and Th2
cytokines measured in cultures of splenocytes from mice administrated DCs
treated under different conditions.
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MATERIALS AND METHODS

Mice

BALB/c and C57BL/6 mice, 7 week of age, were obtained from NCI
(Fredericksburg, MD). Cannabinoid CB1 receptor and CB2 receptor gene
deficient mice (CB1-/- and CB2-/-) on C57BL/6 background were bred by USF
animal facility staff from stocks provided by Dr. Andreas Zimmer (CB1-/-,
University of Bonn) and Dr. Nancy Buckley (CB2-/-, California State Polytechnic
U.). The mice were housed and cared for in University of South Florida Health
Sciences animal facility, which is fully accredited by the American Association for
Accreditation of Laboratory Animal Care.

Reagents

THC, cannabinoid CB1 receptor antagonist N-(piperidin-1-yl)-5-(4chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide
hydrochloride (SR141716A), and cannabinoid CB2 receptor antagonist N-[(1S)endo-1,3,3-trimethyl bicycle [2.2.1] heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4methylbenzyl)-pyrazole-3-carboxamide (SR144528) were obtained from the
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Research Technology Branch of the National Institute on Drug Abuse (Rockville,
MD). SR141716A, SR144528 and THC were first diluted in dimethyl sulfoxide
(DMSO) at 20 mg/ml and then in 5% fetal calf serum RPMI 1640 medium to a
concentration of 0.01-10 µM. 2-Arachidonoylglycerol (2-AG), Virodhamine,
Methanadamide, ACEA, MAFP, DEA, NADA and CP55,940 were purchased
from Tocris (Bristol, UK). AJA was obtained from Dr. Sumner Burstein
(University of Massachusetts, MA) and JWH-133 from Dr. John Huffman
(Clemson University, Clemson, South Carolina). Pertussis toxin (Gi signaling
inhibitor) was purchased from Sigma (St. Louis, MO). Capsazepine (TRPV1
antagonist) was purchased from ALEXIS (San Diego, CA). Pertussis toxin was
dissolved in medium to a concentration of 0.01-1.0 ng/ml. Other cannabinoids
and capsazepine were dissolved in medium to a concentration of 0.01-10 µM.
MAP kinases antagonists UO126, SP600125 and SB203580 were purchased
from Tocris (Bristol, UK).

Bacteria

A virulent strain of Lp (M124), serogroup 1, was obtained from a case of
Legionellosis from Tampa General Hospital (Tampa, FL) and cultured on BCYE
medium (Difco, Detroit, MI) as described previously (89). Bacteria from colonies
of 48 hr cultures were suspended in pyrogen free saline and adjusted
spectrophotometrically to a working concentration.
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Preparation and treatment of bone marrow derived DCs

Bone marrow cells were collected from femurs and tibias of the BALB/c
and C57BL/6 wildtype as well as CB1-/- and CB2-/- mice at 8 to 12 weeks age.
Cells were suspended at 1.0 x 106/ml and cultured overnight in 6-well cell culture
plates (GIBCO-Costar, Cambridge, MA) in RPMI1640 medium supplemented
with 5 µM 2-mercaptoethamol, 2 mM L-glutamine, 1% antibiotic/antimycotic
solution (Sigma), 5% heat-inactivated fetal calf serum (HyClone, Logan, UT) and
10ng/ml granulocyte/macrophage colony-stimulating factor (GM-CSF) (BDPharmingen, San Diego, CA). Non-adherent cells were removed and the
adherent cells were incubated with fresh GM-CSF-containing medium for an
additional 7-9 days, during which time the bone marrow-derived DCs became
nonadherent and were harvested. The purity of the obtained DCs was
determined by flow cytometry staining using fluorochrome-conjugated
monoclonal antibodies to CD11b and CD11c (BD-Pharmingen). The purity was
about 100% CD11b+ and greater than 75% CD11c+ cells. These DCs were
either uninfected or infected with Lp at ratio 10:1 for 30 to 35 min. DCs were
then washed two times to remove non-internalized Lp and re-suspended to106
cells/ml. The cells were treated with different cannabinoids at various
concentrations or with the highest concentration of DMSO or ethanol (vehicle
control). To study the mechanisms involved in THC effect, the DCs were
pretreated with SR141716A or SR144528 at 0.01, 0.05, 0.1 and 0.5 μM or with
capsazepine at 0.01, 0.1, and 1.0 μM. In the study with pertussis toxin, cells
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were cultured for 18 hr with 0.01-1.0 ng/ml pertussis toxin before infected with
Lp. When LPS (Sigma) was used as stimulator, DCs were incubated with LPS
0.01-1 µg/ml and supernatants were collected for cytokine detection at different
time points as indicated. In studies with CD4 T cells, cells were obtained from
mice intravenously (iv) infected (primed) with a sub-lethal dosed of Lp (7 x 106)
and the spleens were removed 5 days post-infection. The T cells were isolated
from the splenocytes by mouse T cell Enrichment Columns (R&D system,
Minneapolis, MN) and CD4+ T cells were negatively selected from the purified T
cells with CD4 enrichment magnetic bead kits (BD-Pharmingen). Isolated CD4 T
cells were then dispensed in 24-well cell culture plates (GIBCO-Costar) and cocultured with DCs (CD4: DC = 10:1) in either the absence or presence of
recombinant IL-12p40 (BD-Pharmingen) for 24 hr followed by cytokine analysis.

Cell surface marker analysis by flow cytometry

To evaluate the effects of THC on MHC class II, CD86 and CD40
expression on DCs, cells, either uninfected or infected with Lp, were treated with
DMSO or THC 10 µM for 48 hr. Following incubation, the cells were treated with
fluorochrome-conjugated mAbs (BD-Pharmingen) at 4°C for 30 min, and then
washed in PBS containing 2% BGS, and fixed in 1% paraformaldehyde. Cells
were analyzed using FACScan (Becton Dickinson, Mountain View, CA). The
instrument is equipped with lasers tuned to 488 nm and to 635 nm. The following
fluorochrome-conjugated mouse mAbs were used for DC surface marker
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staining: PE-conjugated anti-MHC class II; PE-conjugated anti-CD86; and PEconjugated anti-CD40 (BD Pharmingen).

Bacteria growth determined by CFU assay

After 24 hr infection, spleens from infected mice were homogenized in
Hanks balanced salt solution (HBSS). In studies of Lp growth in DC cultures,
cells were lysed by with 0.1% saponin (Sigma) and diluted in HBSS.
Homogenized spleens or lysed DCs were plated on BCYE agar plates and
incubated at 37°C for 72 hr. CFU counts were determined on an AutoCount
apparatus (Dynatech Labs, Chantilly, Va.).

Cell viability and apoptosis detection

DC viability and apoptosis were detected using the Annexin V-FITC kit (
BD-Pharmingen). Briefly, uninfected or infected cells (105), treated with DMSO
(LpDC/DMSO) or THC 10 µM for 24 hr (LpDC/THC), were washed twice with
PBS, and incubated with Annexin V-FITC (5 µl) and propidium iodide (5 µl) in
binding buffer for 15 min. Early apoptotic cells (Annexin V positive and propidium
negative) and late apoptotic or dead cells (Annexin V positive and propidium
positive) were quantitated by flow cytometry.
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Cytokine detection by ELISA

IL-12p40, IL-4, IL-23 and IL-10 were determined using a sandwich ELISA
with antibody pairs from BD Pharmingen. In 96-well enzyme immunoassay
plates (GIBCO-Costar), each well was coated with 50 µl of anti-murine antibody
in 0.1 M NaHCO3, pH 8.2 (anti-IL-12 p40 for IL-12p40 and IL-23; 5 µg/ml) or in
PBS (anti-IL-4 and anti-IL-10; 2 µg/ml) overnight at 4oC. The wells of the plate
were blocked with 150 µl of 3% BSA/0.05% Tween 20 in PBS (IL-12p40 and IL23) or 0.5% BSA/0.05% Tween 20 in PBS (IL-4, IL-10) and incubated for 1 hr.
The culture supernatants or serial dilutions of cytokine standards were added
and incubated for 1-2 hr, followed by biotinylated detection antibodies (2ug/ml,
50ul) for 1 hr, and streptavidin-horseradish peroxidase (HRP) (1:1000 in 50ul) for
30 min. The plates were washed between each addition. The tetramethyl
benzidine (TMB; Sigma) substrates were developed for 5-30 min; the reaction
was stopped with 1 N sulfuric acid and read at 450 nm on an Emax microplate
reader (Molecular Devices; Menlo Park, CA). The concentrations of sample
cytokines were calculated from standard curves that were done for each plate.
The levels of IFN-γ and IL-12p70 in supernatants were measured using BD
OptEIATM Sets (BD Pharmingen) according to the manufacturer instructions.
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Cell-based ELISA

Phosphorylation of p38, JNK and ERK1/2 were measured by Fast
Activated Cell-Based ELISA kits from Active Motif (Carlsbad, CA). Briefly, 96well culture plates were treated with 100 µl 10 µg/ml poly-L-Lysine for 30 min at
37oC and then washed twice with PBS. uninfected DCs or Lp-infected DCs were
then seeded into 96-well plates with culture medium containing THC (6µM) for
indicated time. Cells were fixed by replacing the culture medium with 100 µl of
8% formaldehyde in PBS. After 20 min incubation at room temperature, plates
were washed three times with wash buffer (PBS containing 0.1% Triton X-100).
Cells were then incubated with quenching buffer (wash buffer containing 1%
H2O2 and 0.1% Azide) to inactivate the cells endogenous peroxidase activation.
After 20 min, cells were washed twice and incubated with antibody blocking
buffer 100 µl for 1 hr and incubated overnight with primary antibody for phosphoMAP kinase protein or total-MAP kinase at 4°C. Next day, cells were washed
three times incubated with horseradish peroxidase-conjugated secondary
antibody for 1 hr at room temperature and washed three times with wash buffer
and twice with PBS. Subsequently the cells were incubated with 100 µl
developing solution for 2-20 min at room temperature; the reactions were
stopped by adding 100 µl stop solution and absorbance was read on an Emax
microplate reader (Molecular Devices). Levels of MAP kinase activation were
expressed as the ratios of phosphorylated MAP kinase to total MAP kinase.
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Reverse Transcription Polymerase Chain Reaction (RT-PCR)

Total RNA was extracted from dendritic cell cultures by standard
techniques using TriReagent (Sigma) and quantitated using RiboGreen RNA
Quantitation Kit (Molecular Probes, Eugene, OR). The extracted RNA was
treated with DNase using DNA-free kit from Ambion (Austin, TX). 1µg of total
RNA were used for cDNA synthesis at 42oC for 45 min by priming with 0.5 µg
oligo (dT)15 primer, 20 nmol each deoxynucleoside triphosphate, 0.5 U RNase
inhibitor, and 15 U avian myeloblastosis virus reverse transcriptase (Promega,
Madison, WI) in a total volume of 25 µl. 2 µl of the reverse transcriptase product
was used for PCR, which was carried out in PCR buffer (TaKaRa, Fisher;
Atlanta, GA) containing 250 µM dNTP, 1.0 µM each primer and 2.5 U Tag DNA
polymerase (TaKaRa). The primer pairs used were as follows: cannabinoid CB1
receptor forward primer, 5'-TCACCACAGACCTCCTCCTCTAC-3'; reverse
primer, 5'-CTCCTGCCGTCATCTTTTC-3' (149 bp product); cannabinoid CB2
receptor forward primer, 5'-GTACATGATCCTGAGCAGTGG-3'; reverse primer
5'-TGAACAGGTACGAGGGCTTTCT-3' (147 bp product); TRPV1 forward primer,
5'-AATTTGGGATGTGGAGCAAG-3'; reverse primer, 5GATCCCCCGAGTATCCATTT-3' (176 bp product); β-actin forward primer, 5'GGGAATGGGTCAGAAGAACT-3'; reverse primer, 5'AGGTGTGGTGCCAGATCTTC-3' (133 bp product); Jagged1, forward primer, 5'AGAAGTCAGAGTTCAGAGGCGTCC-3', reverse primer, 5'AGTAGAAGGCTGTCACCAGCAAC-3' ( 113 bp product); Delta4, forward primer,
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5'-AGGTGCCACTTCGGTTACACAG-3', reverse primer 5'CAATCACACACTCGTTCCTCTCTTC-3' (123 bp product); and β-actin, forward
primer, 5'-ATGGATGACGATATCGCT-3', reverse primer, 5'ATGAGGTAGTCTGTCAGGT-3' (530 bp product). All PCR were performed in a
Mastercycler (Eppendorf, Westbury, N.Y.) at 60oC for annealing. The number of
cycles in each PCR was as follows: CB1, CB2, TRPV1 and β-actin (133bp), 40
cycles; Jagged1 and Delta4, 35 cycles; and β-actin (530bp), 28 cycles. PCR
products were analyzed on ethidium bromide-stained, 2% agarose gels. RTnegative amplifications were also done to control for contaminating genomic
DNA.

Animal injections and tissue sampling

Mice were immunized iv with 0.3-0.5 x 106 treated DCs suspended in PBS,
and 7-9 days later spleens were isolated from mice. Single-cell suspensions of
splenocytes (2 x 106 cells/ml) were cultured with formalin-killed Lp (107/ml) for 24
hr and supernatants collected for cytokine detection. Or, DC-treated mice were
challenged iv with live Lp (sublethal dose, 7 x 106) diluted in pyrogen free saline.
Spleens were obtained after 24 hr and CFUs of Lp were counted. In other
experiments, mice were immunized iv with DCs (0.5 x 106) for two or three times
at 7 day interval, challenged iv with a lethal dose of Lp (1.7-2.0 x 107) and
survival of mice was monitored.
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Statistical analysis

Data were analyzed by one-way analysis of variance with Dunnett’s test
for comparing individuals using SigmaStat (Jandel Scientific, San Rafael, CA), or
using the two-tailed Student’s t test. A value of p < 0.05 was accepted as
indicating significance.
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RESULTS

Aim 1. To determine the effect of cannabinoids on the polarizing phenotype
of DCs infected with Lp

Lp infection of DCs induced IL-12p40 production

IL-12 is a heterodimer produced by DCs and formed by the association of
a 35-kDa light chain (p35) and a 40-kDa heavy chain (p40). Interestingly,
microbial components alone seem to induce primarily p40 with relatively low
amounts of IL-12p70 (28). Based on this, the kinetics of the IL-12p40 subunit
production was investigated to determine the bone marrow-derived dendritic cell
response to Lp infection. Dendritic cell cultures were infected, supernatants
harvested at indicated time points, and supernatant IL-12p40 was measured by
ELISA. As shown in Figure 2, there was a rapid increase in the secretion of the
p40 protein reaching a peak by 44 hr following infection. These data indicate that
cultured bone marrow-derived DCs produce IL-12p40 following infection with
Legionella.
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Suppression by THC of Lp-induced IL-12p40 secretion

To determine if cannabinoids can modulate the ability of DCs to produce
IL-12p40, infected DCs were treated with increasing concentrations of THC (0, 1,
3, 6 and 10 µM) and incubated for 24 hr followed by IL-12p40 measurements.
Figure 3 A shows that THC treatment led to a significant decrease in IL-12p40 at
a concentration of 3 µM and higher while drug vehicle (DMSO) had no effect. In
addition, Figure 3 B shows that the THC (10µM) suppression effect on DC IL12p40 was observed as early as 6 hr after treatment and Lp infection. These
data demonstrated THC consistently and significantly suppressed DC secretion
of IL-12p40.

No suppressive effect by THC on LPS-induced IL-12p40 production

To examine if the THC effect is related to TLR4 signaling, we used LPS, a
ligand for TLR4, as a stimulant in DC cultures. Compared with Lp infection, LPS
induced a rapid increase in IL-12p40 (Figure 4 A) that reached maximum at 12 hr
after stimulation. However, unlike with Lp infection, THC treatment had no
significant effect on LPS-induced IL-12p40 production (Figure 4 B). These data
suggest that Lp infection stimulates IL-12p40 through receptors other than TLR4
and that the THC suppressive effect is not generalized for all stimuli but selective
for mechanisms related to Lp infection rather than the TLR4/LPS pathway.

29

Other non-selective agonists suppressed IL-12p40 production

In addition to the effect of THC on DC function, we also examined the
effect of the endocannabinoids 2-AG and Virodhamine. 2-AG has been shown to
be produced in DC cultures (113) and Virodhamine has been reported in rat
peripheral tissues including immune organs such as spleen in higher levels than
AEA, another endocannabinoid (148). 2-AG and Virodhamine are potent
agonists for both CB1 and CB2 (119, 148, 172) and there are no reports
examining their functional effects on DCs. We therefore treated Lp-infected DCs
with various concentrations of 2-AG and Virodhamine. We found that 2-AG
treatment significantly suppressed IL-12p40 at concentrations of 1 µM and 10 µM
(Figure 5 A). No effect was observed with ethanol as the drug vehicle control.
Virodhamine also showed significant suppression at 10 µM and the suppression
level was comparable to 2-AG, though not as strong as THC used at the same
concentration (Figure 5 B). In addition, we tested other endogenous ligands,
such as NADA and DEA, that are both CB1 selectvie and produced in nervous
tissues (12, 16, 36, 61, 73). We also tested the synthetic cannabinoids including
the CB1 selective agonists ACEA, AJA, M-AEA (1, 46, 64, 80), and the CB2
agonist JWH-133 (74). The results showed these agents did not significantly
suppress IL-12p40 in Lp infected DCs (data not shown). Thus, nonselective
cannabinoid receptor agonists, including THC, 2-AG and Virodhamine, but not
other agonists, led to a significant inhibition of IL-12p40 production in our culture
system.
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THC suppressed the expression of DC maturation and polarizing markers

Upon exposure to microbes, DCs are activated to go through a maturation
process characterized by an increase in surface expression of MHC class II
proteins and co-stimulatory molecules contributing to initiation of an effective
adaptive immune response (76). To determine if THC modulates this polarizing
DC phenotype, we treated infected and non-infected DCs with either DMSO or
THC and assessed the expression of these surface markers. After 48 hr, we
observed by flow cytometry that Lp infection increased the surface expression of
CD86 and CD40; however, THC treatment significantly suppressed the
expression of both markers (Figure 6 and Table 1). Regarding MHC class II, we
observed that although expression was high in all three groups, the intensity per
cell of the marker was enhanced in the Lp infected-DCs but was significantly
decreased by THC treatment (Table 1). From these results, it is possible that
drug suppression of T helper polarization is due in part to a down-modulation of
these phenotypic markers. Other surface proteins such as Notch receptors are
known to regulate T cell development (151). Recently it was shown that the
Notch ligands, Delta4 or Jagged1 on DCs promote induction of either Th1 or Th2
activity, respectively (6). We, therefore, examined the relative mRNA expression
of these ligands in DCs loaded with Lp and treated with THC or vehicle for 18 hr.
We observed that mRNA for both ligands was increased in DCs after Lp infection
(LpDC/DMSO group; Figure 7) but that the Delta 4 band intensity relative to β31

actin was decreased following THC treatment suggesting that the message level
of this Th1 polarizing ligand was decreased by drug treatment.

THC treatment did not affect Lp survival in DCs or enhance apoptosis of
infected DCs

THC has been observed to induce apoptosis in macrophages and
lymphocytes (193) and also in DCs (43); therefore, it could be argued that drug
suppression of IL-12 production and marker expression could be due to a toxic
effect on DCs. Also, antigen presentation to CD4 T cells by DCs requires
internalization and procession of infectious agents by the DCs and drug-induced
suppression of phagocytosis, therefore, might contribute to suppression of T cell
activation. In order to test the THC effect on these other relevant DC functions,
we studied the drug effect on the survival of Lp in DCs and the induction of
apoptosis in Lp-infected DCs. DCs were infected with Lp for 30 min followed by
washing to remove non-internalized bacteria. Infected cultures were then treated
with THC or DMSO for 0, 24 and 48 hr and the number of cell-associated CFUs,
as a measure of phagocytized bacteria, was determined by cell lysis and viable
bacteria colony counts. The results (Figure 8) showed that the bacteria
internalizing function as measured by intracellular survival was unaffected by
THC treatment. Both drug-treated and vehicle treated cells restricted the growth
of Lp in an equivalent manner over time. To determine if THC induced apoptosis
in Lp-infected DCs, staining with propidium iodide and annexin V in treated DCs
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was analyzed by flow cytometry. Compared with uninfected DCs, the percentage
of apoptotic cells, assessed as single positive for annexin V, was enhanced after
Lp infection (Figure 9), and treatment with THC did not increase the annexin
positivity. Furthermore, analysis of propidium iodide staining, as indicative of
necrotic cells, was similar in infected and infected plus THC treated cells. The
data suggest THC treatment did not affect the degree of apoptosis or processing
of bacteria in DCs following Lp infection.

Aim 2. To determine the role of cannabinoid receptors in drug effects on
DC polarization

Expression of cannabinoid and vanilloid receptor mRNA in DCs

The cannabinoid receptors identified so far are CB1 and CB2. Both have
been reported to be involved in the THC-induced attenuation of IL-12 production
in drug-treated mice infected with Legionella (89). Moreover, TRPV1, has
recently been shown to bind AEA and other endocannabinoids and mediate their
effects (96, 180, 196). To examine receptor expression in dendritic cell cultures,
RNA was isolated from DCs and analyzed by RT-PCR for CB1, CB2, and TRPV1
messages. Figure 10 shows mRNA of both cannabinoid receptors and TRPV1
was readily detected in DCs and the level of cannabinoid CB2 receptor and
TRPV1 messages appeared to be more abundant than CB1 receptor (Ratios of
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target genes to β-actin are: CB2 receptor 0.76, TRPV1 0.84, and CB1 receptor
0.48).

Pertussis toxin attenuated THC-induced suppression of IL-12p40

Cannabinoid receptors are Gi protein-coupled receptors. Gi signaling is
suppressed by pertussis toxin and the toxin has also been reported to suppress
IL-12 production (19, 89). To examine if THC -induced suppression of IL-12p40
is through Gi protein-coupled mechanisms, DCs were pretreated with different
concentrations of pertussis toxin (0.01, 0.1, or 1.0 ng/ml) for 18 hr followed by Lp
infection and THC (3, 6 or10 µM) treatment for 24 hr. Pertussis toxin (at 1.0
ng/ml) completely reversed the suppression effect of THC at low concentrations
(3 or 6 µM) (Figure 11). However, the effect of THC at a higher concentration (10
µM) was only partially attenuated by pertussis toxin (Figure 11). This finding
suggests the involvement of Gi protein-coupled mechanisms in the suppression
of IL-12p40 at low THC concentrations, but other suppressive mechanisms at
higher concentrations.

Role of cannabinoid receptors in THC-induced suppression of IL-12p40

To fully examine if cannabinoid receptors were involved in suppression of
IL-12p40, experiments were performed using CB1-/- (194) and CB2-/- (23) mice.
Because the knockout mice are on the C57BL/6 background and our previous
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studies had been done with BALB/c mice, we first tested the response of bone
marrow-derived DCs from wild-type C57BL/6 mice in terms of IL-12p40 production
and suppression by THC. Comparing Figure 12 A, to Figure 3 A shows that cells
from C57BL/6 mice displayed a comparable suppressive response to those from
BALB/c. We next studied the response of DCs from CB1-/- and CB2-/- mice and the
results showed that both were suppressed by THC similar to wild-type cells
(Figure 12, panels B and C). Since THC is a non-selective receptor agonist and
can bind both CB1 and CB2 receptors (51), it is possible that the drug could have a
relatively unimpeded effect in cells from single receptor knockout mice. To
examine this possibility, the specific antagonists for CB1 (SR141716A) and CB2
(SR144528) were used in combination with cells from knockout mice. CB1-/- DCs,
after Lp addition, were pretreated with SR144528 at different concentrations for
30 min prior to THC treatment and the reciprocal experiment was performed using
CB2-/- and SR141716A pretreatment. After 24 h, supernatant IL-12p40 was
assessed by ELISA. As a control, cultures were treated with either SR141716A or
SR144528 only followed by infection and no effect on IL-12p40 was observed (not
shown). Table 2, shows the SR compounds attenuated the THC effect in
knockout mice, especially at the lower drug concentrations. For example, the
attenuating effect of SR144528 (at 0.1 µM) in CB1-/- cells is nearly 70% of control
at 3 µM THC but only 28% of control at 10 µM THC. A higher concentration of
SR144528 (0.5 µM) had the identical attenuating effect (data not shown). Similar
decreases in receptor antagonist efficacy with increasing receptor agonist
concentration were seen using CB2 -/- cells (Table 2). These results suggest that
35

cannabinoid receptors are involved in the THC-induced suppression of p40,
especially at the lower drug concentrations, but that other mechanisms become
involved as the THC concentration is increased.

TRPV1 was not involved in THC effect

From the above, it appears that mechanisms other than cannabinoid
receptors are involved in THC suppression of IL-12p40. Therefore, we tested for
a possible role of TRPV1 in the THC effect by pre-treating with capsazepine, the
specific receptor antagonist for TRPV1. Dendritic cell cultures were infected with
Lp and treated with either THC alone (3 and 10 µM) or in combination with
capsazepine at 0.01, 0.1, and 1.0 μM. As shown in Figure 13, there was no
attenuating effect of capsazepine on the THC effect suggesting that TRPV1
receptors were not involved in the response.

The activation of p38 MAP kinase was modulated by THC

It is reported that MAP kinases can be activated in response to ligands for
G protein-coupled receptors, and many studies have indicated kinase activation
affects either positively or negatively IL-12 production (18, 179, 186). There are
three major groups of MAP kinases in mammalian cells: the extracellular signalregulated protein kinases (ERK), the p38 MAP kinases, and the c-Jun-NH2terminal kinases (JNK)(44). Many studies have suggested the modulation effect
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of various cannabinoids on MAP kinase activity (69). However, a role for these
kinases in the THC effect on DC cytokine production has not been reported
(158); therefore we examined the role of kinase activity in our system. Initially we
treated Lp-infected DCs with specific antagonists for different kinases for 18 hr
and then measured IL-12p40. We found that only the p38 inhibitor, SB203580,
but not Erk inhibitor, UO128, nor JNK inhibitor, SP600125, was able to suppress
IL-12p40 production suggesting only p38 kinase activation is required for Lpinduced IL-12p40 secretion (Figure 14). From this finding, we next examined the
effect of THC on p38 activation in DCs during Lp infection. As shown in Figure
15, Lp infection induced an increase in phosphorylated p38 protein within 10 min
after infection indicating an up-regulation in p38 activity. THC treatment,
interestingly, initially increased phosphorylated p38 but then caused a drop in the
level by 3 hr after infection. From these studies it is clear that p38 kinase is an
important signaling component of the Lp induction of IL-12p40 and that
modulation of p38 phosphorylation by THC might be a critical mechanism of drug
action.
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Aim 3. To determine the effect of THC treatment on the T helper polarizing
function of DCs

THC treatment impaired the immunization potential of Lp-loaded DCs

Due to the pivotal role in stimulating T cells, DCs loaded with specific
antigens have been utilized as immunizing vehicles in numerous studies of
tumor therapies (29, 195) and infectious diseases (126). To test whether DCs
loaded with Lp would induce a specific immune response and if THC would
impair this ability, we treated Lp-infected DCs in culture with 10 µM THC
(LpDC/THC) or drug vehicle DMSO (LpDC/DMSO) for 24 hr. DCs without
infection and drug treatment were incubated for the same time as controls.
Following treatment, DCs were injected iv into mice two to three times at 7 day
intervals, and seven days after the last injection, the mice were challenged with a
lethal dose (1.7-2.0x107) of bacteria and survival monitored. The results in Figure
16 showed that uninfected DCs failed to induce protection as none of the mice
survived; however, Lp-loaded DCs (LpDC/DMSO) induced significant protection
with a survival ratio of 66 percent (6/9). However, mice receiving loaded DCs
treated with THC (LpDC/THC) showed no survival after 25 hr indicating a lack of
immunizing potential similar to mice injected with non-loaded DCs. In other
experiments to examine immunizing potential, mice were injected with DCs,
LpDC/DMSO or LpDC/THC (0.3-0.5x106) and seven to nine days later
challenged with a sublethal dose (7x106) of Lp rather than a lethal dose as in the
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above experiments. After 24 hr, spleens were isolated and homogenized, and
bacterial burdens measured by CFU analysis. The data showed that spleens
from mice receiving Lp-loaded DCs had much lower CFUs than spleens from
mice receiving either unloaded DCs or loaded DCs treated with THC (Figure 17).
These findings together demonstrated that mice immunized with Lp-loaded DCs
were able to induce immunization against Lp infection and that THC treatment
significantly attenuated this effect.

THC treatment of Lp-loaded DCs inhibited Th1 activity in splenocytes from
recipient mice

Type 1 cytokines, including IL-12 and IFN-γ, can be measured in immune
organs and are a measure of the development of protective immunity against
intracellular microbial infections (150). To determine polarization toward Th1
immunity, the cytokine profiles in splenocytes of mice immunized with the various
DC populations were analyzed to determine whether THC treatment of DCs
suppressed an upregulation of Th1 activity in recipient mice. As in the transfer
experiments above, mice were immunized with DCs only, Lp-loaded DCs, or
loaded DCs treated with THC, and seven to nine days later splenocytes were
harvested from the recipient mice and stimulated in vitro for 24 hr with specific Lp
antigens. Supernatants from these cultures were collected and analyzed for
type1-associated cytokines by ELISA. As shown in Figure 18, the splenocytes
from mice receiving Lp-loaded DCs treated with DMSO produced 1.5-2 fold
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increases in IL-12p40 and IFN-γ as compared to splenocytes from mice treated
with unloaded DCs. This suggested an upregulation of Th1 activity in the spleens
of mice immunized with Lp-loaded DCs accounting for their enhanced resistance
to Lp infection (see Figure 16 and 17). However, THC treatment of the DCs
inhibited this upregulation of Th1 activity, suggesting an attenuation of the
immunizing potential of these cells (Figure 18 A and B). IL-4 production by
splenocytes was also examined and we observed it was suppressed following
injection of Lp-loaded DCs either treated or not with THC (Figure 18 C). This
suggested that the increase in Th1 activity in the spleens coincided with a
decrease in the Th2 cytokine, IL-4; furthermore, it suggested that THC
suppressed Th1 cytokines by mechanisms other than the upregulation of IL-4.
The data overall suggested that THC treatment of antigen-loaded DCs can
suppress the immunizing and Th1 polarizing potential of these cells when
subsequently injected into mice.

IL-12p40 addition restored the polarizing function of THC-treated DCs

We have shown above that THC suppresses the production of IL-12p40 in
Lp-infected DC cultures. Therefore, to examine if this attenuation is responsible
for the impaired Th1 polarizing function of these cells, co-cultures of DCs with T
cells from both unprimed and Lp-primed animals were prepared to examine the
reconstitution efficacy of exogenously added IL-12p40. Figure19 A shows results
from co-cultures of Lp-loaded DCs and unprimed CD4 T cells. Lp loading of DCs
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induces the production of IL-12p40 as detected in culture supernatants by ELISA
and THC treatment of the cells suppressed this response. The addition of
unprimed T cells had little effect on IL-12 production (Figure 19 A) and in studies
not shown, no IFN-γ was detected in these cultures. We next examined the
accessory cell potential of drug treated DCs in cultures containing Lp-primed T
cells and supplied with various concentrations of IL-12p40. Figure 19 B shows
that DCs plus primed T cells (LpCD4) produced a relatively small amount of IL12p40; however, when DCs were loaded with Lp (LpDC/DMSO), a robust IL12p40 response was evident and this was significantly attenuated by THC
treatment (LpDC/THC + LpCD4). Of interest was the finding that the addition of
recombinant IL-12p40 protein to the cultures increased the IL-12 supernatant
concentrations above the amounts added (Figure 19 B). For example, addition
of 0.5ng/ml recombinant IL-12p40 resulted in an increase of supernatant IL-12
from 2ng to 6ng/ml. Furthermore, in contrast to co-cultures containing unprimed
CD4 T cells, cultures containing primed T cells, produced in addition to IL-12p40,
robust amounts of IFN-γ but only in the presence of Lp-loaded DCs (Figure 19 C)
and this effect was attenuated by THC treatment of the DCs. However, the
addition of recombinant IL-12p40 completely restored IFN-γ production
suggesting a restoration of Th1 polarization by IL-12. In addition to IL-12p40, we
also tested for the presence of IL-12p70, IL-23, and IL-10 in the culture
supernatants. These cytokines were not detected suggesting that the
suppression of IL-12p40 by THC treatment was primarily responsible for the
reduced Th1 polarization.
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Figure 1. THC suppressed the production of IL-12p40 and IL-6 in bone
marrow-derived DCs. L. pneumophila (Lp) infected DCs were treated with
DMSO (Lp), or THC 6 µM for 24 hr. Supernatants were collected for cytokines
detection. Data represent the mean of 3 experiments ± S.E.M.. *P< 0.05,
compared to Lp group.
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Figure 2. Lp infection induced IL-12p40 production in bone marrow-derived
DCs from BALB/c mice. Immature bone marrow-derived DCs were infected as
indicated in the methods. Supernatants were collected at indicated time points
and IL-12p40 measured by ELISA. Data represent the mean of 4 experiments ±
S.E.M..
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Figure 3. THC, in a concentration-dependent manner, suppressed IL-12p40
production in Lp-infected BM-DCs from BALB/c mice. (A) Lp-infected BMDCs were treated with different concentrations of THC or the highest
concentration of DMSO (vehicle control) for 24 hr. (B) Using THC at 10μM, THC
suppresses IL-12p40 production at 6, 12, and 21 hr. Data represent the mean of
3-5 experiments ± S.E.M.. *P< 0.05, compared to Lp group (THC 0 µM).
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Figure 4. No significant effect of THC on LPS-induced IL-12p40 from DCs.
(A) immature BM-DCs were incubated with LPS (1 µg/ml). Supernatants were
collected at indicated time points and IL-12p40 measured by ELISA. (B) DCs
were stimulated with LPS (10 ng/ml) and treated with different concentrations of
THC or the highest concentration of DMSO (vehicle control) for 24 hr.
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Figure 5. Cannabinoid receptor agonists 2-AG and Virodhamine in a
concentration-dependent manner, suppressed IL-12p40 production in Lpinfected bone marrow-derived DCs from BALB/c mice. Lp-infected DCs were
treated with different concentrations of 2-AG or the highest concentration of
Ethanol (ETOH, vehicle control) (A) or Virodhamine with different concentrations
or THC or 2-AG at 10 µM (B) for 24 hr. IL-12p40 was detected by ELISA and the
data represent the mean of 3-5 experiments ± S.E.M.. *P< 0.05, compared to 2AG 0 µM (A) or Virodhamine 0 µM (B).
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Figure 6. THC suppressed the expression of maturation markers on Lp
infected-DCs. Cell surface markers were determined by flow cytometry on DCs
treated for 48 hr in various ways: uninfected (DC); Lp-infected and DMSO treated
(LpDC/DMSO); and Lp-infected and THC (10 µM) treated (LpDC/THC). Data are
expressed as percent expression (%) of the surface marker and mean
fluorescence intensity (MFI) of the population for the marker. Data are
representative of 4 experiments.
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Table 1. THC treatment suppressed DC maturation markers. Cell surface
markers were determined in uninfected DCs (DC), Lp-infected and DMSO
treated cells (LpDC/DMSO) or THC (10 µM) treated cells (LpDC/THC) by flow
cytometry after 48 hr treatment.

Percent Expression
DC

LpDC/DMSO

LpDC/ THC

MHC class II

82.3 ± 11.2a

87.2 ± 6.0

79.4 ± 4.8

CD86

63.8 ± 3.1

81.7 ± 2.8#

53.7 ± 5.4*

CD40

37.7 ± 7.9

70.1 ± 5.6#

36.5 ± 9.6*

Fluorescent intensity per cell
DC

LpDC/DMSO

LpDC/ THC

MHC class II

2212.1 ± 499.5 b

2693.7 ± 313.1

1433.5 ± 348.6*

CD86

147.1 ± 8.6

183.7 ± 22.1

133.2 ± 12.7

CD40

83.4 ± 21.4

130.3 ± 29.6

81.0 ± 9.2

a = Percent +/- SEM, n=4
b =Mean fluorescence intensity +/- SEM; n=4
# = p <0.05 versus the uninfected DC control
* = p <0.05 versus LpDC/DMSO group
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DC

LpDC/
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LpDC/
THC

1.1*

1.8

2.1
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Delta4
0.3
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0.2

β-actin
* Target to β –actin ratio

Figure 7. THC suppressed the expression of Delta 4 in Lp-infected DCs
(LpDC/THC) as compared to infected DCs treated with DMSO
(LpDC/DMSO). DCs were uninfected or infected with Lp and treated with DMSO
or THC (10 µM) for 18 hr. Jagged1, Delta4, and β-actin mRNAs were amplified
by RT-PCR. Data are representative of 3 experiments.
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Figure 8. Lp uptake and survival were not affected by THC treatment of Lp
infected-DCs. DCs infected with Lp for 30 min, washed twice to remove noninternalized bacteria and treated with DMSO or THC (10 µM) for 0, 24, 48 hr. At
various time post-infection, cell lysates were harvested and plated on agar
medium, and CFUs of Lp determined by plate counts at 72 hr. Data represent
the mean of 3 experiments +/- SEM.
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Figure 9. Apoptosis and cell death were not affected by THC treatment.
Cultures of DCs were untreated (DC) or treated for 24 hr with either DMSO
(LpDC/DMSO) or THC at 10 µM (LpDC/THC) and apoptosis and cell death were
analyzed by staining with Annexin V and propidium iodide, respectively. (A) Dot
plot of propidium iodide and Annexin V staining; representative of 3 similar
experiments. (B) Percent of apoptotic cells (Annexin V+; propidium iodide-) and
dead cells (propidium iodide+); mean +/- SEM , n=3. #, p <0.05 versus DC
control.

51

A

1

12
DC
20

14

1

LpDC/
DMSO
40

18

Propidium iodide

1

LpDC/
THC
40

Annexin V

B

52

200 bp

Figure 10. Demonstration by RT-PCR of cannabinoid receptor, TRPV1 and
β-actin message in RNA from bone marrow-derived DCs. Negative RT
represents PCR results when the reverse transcriptase is left out of reaction mix.
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Figure 11. Pertussis toxin, the Gi signaling inhibitor, attenuated the
suppression effect of THC on IL-12p40. Bone marrow-derived DCs were
preincubated with pertussis toxin at 0.01, 0.1, 1.0 ng/ml 18 hr prior to Lp infection
and treated with THC 0, 3, 6 and 10 µM. Cells were incubated for 24 hr and data
represent the mean of 3 experiments ± S.E.M.. *P< 0.05, compared to THC + Lp
group.
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Figure 12. THC suppressed IL-12p40 production in Lp-infected bone
marrow-derived DCs from C57BL/6 mice. (A) THC suppresses IL-12p40 in
DCs from wild type (WT) mice. (B and C) THC suppresses IL-12p40 in
cannabinoid CB1 receptor knockout (CB1-/-) and CB2 receptor knockout (CB2-/-)
mice. Lp-infected DCs were treated with different concentrations of THC or the
highest concentration of DMSO (vehicle control). Cells were cultured for 24 hr.
Data represent the mean of 3 experiments ± S.E.M.. *P< 0.05, compared to
THC 0 µM.
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Table 2. Attenuation effect of SR compounds on THC-induced suppression
of IL-12p40 in Lp-infected bone marrow-derived DCs from cannabinoid
receptor knockout mice. Lp-infected DCs were pretreated with SR144528
(CB1-/- DCs) or SR141716A (CB2-/- DCs) at 0.01, 0.05, or 0.1 µM for 30 min prior
to THC (3, 6 or 10 µM). Cells were cultured for 24 hr and the data represent the
mean of 4 experiments ± S.E.M.. SR alone at these doses had no effect on IL12p40 production (not shown). The percentage of attenuation is computed from
1-[IL-12p40(Lp-SR/THC/Lp)/Lp]/[IL-12p40(Lp-THC/Lp)/Lp].

CB1-/THC (µM)

3

6

10

SR144528
(µM)
0.01
20.0 ± 6.0

Attenuation (%)
18.2 ± 8.8

8.4 ± 1.5

0.05

59.5 ± 8.7

37.0 ± 5.7

15.8 ± 5.0

0.1

69.6 ± 7.0

44.7 ± 2.5

27.9 ± 2.0

CB2-/THC (µM)

3

6

10

SR141716A
(µM)
0.01
24.1 ± 7.8

Attenuation (%)
18.9 ± 4.2

3.0 ± 1.6

0.05

38.0 ± 5.1

33.2 ± 4.1

14.7 ± 5.8

0.1

61.1 ± 8.5

39.9 ± 7.0

24.2 ± 5.7
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Figure 13. Vanilloid receptor inhibitor Capsazepine did not antagonize the
suppression effect of THC on IL-12p40. Lp-infected DCs were pretreated with
Capsazepine at 0.01, 0.1 and 1 µM for 30 min prior to THC (3 or 10 µM). Cells
were cultured for 24 hr and the data represent the mean of 3 experiments ±
S.E.M..
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Figure 14. p38 MAP kinase, but not JNK or ERK was required for IL-12p40
production in Lp-infected DCs. Lp-infected DCs were treated with ERK
inhibitor UO126 (5 µM), or JNK inhibitor SP600125 (5 µM) or p38 inhibitor
SB203580 (5 µM) for 18 hr. IL-12p40 in supernatants was detected by ELISA
and the data represent the mean of 3 experiments ± S.E.M.. *P< 0.05, compared
to Lp group.
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Figure 15. THC modulated p38 MAP kinase activation. DCs were either
uninfected or infected with Lp or treated with THC (6 µM) following infection.
Cells were fixed at indicated time points and the levels of p38 kinase expression
were measured by cell-based ELISA. Data are expressed as the ratio of
phosphorylated p38 to total p38 in DCs. Data represent the mean of 3
experiments ± S.E.M.. *P< 0.05, compared to Lp group.
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Figure 16. THC impaired immunization potential of Lp-loaded DCs. Naïve
mice were iv immunized with DCs (0.5x106 cells/mouse) two to three times at 7
day intervals prior to being challenged with a lethal dose of Lp (1.7 - 2.0
x107/mouse). The DCs were either not loaded with Lp (DC group) or loaded with
Lp and treated for 24 hr with either DMSO (LpDC/DMSO group) or THC, 10 µM
(LpDC/THC group). Mice were monitored for survival and the data represent 9
mice per group from 3 experiments.
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Figure 17. THC treatment of Lp-loaded DCs inhibited immunizing potential
as evidenced by increased bacterial burden. Mice were iv injected with 0.30.5x106 DCs loaded or not in vitro with Lp and treated with DMSO
(LpDC/DMSO), or THC at 10 µM (LpDC/THC) for 24 hr. Then, mice were
challenged 7-9 days later with a sublethal dose of Lp (7x106 Lp/mouse),
spleens isolated 24 hr post-infection, and colonies forming units (CFU)
determined by plate counts. Data presented as the mean CFU +/- SEM for 4
mice per group. # and * (p <0.05) versus the uninfected DC control and
LpDC/DMSO group, respectively.
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Figure 18. THC treatment of Lp-loaded DCs inhibited the expression of Th1
cytokines in splenocytes from immunized mice. Mice were iv injected with
control DCs (0.3-0.5x106), Lp-loaded and DMSO treated DCs (LpDC/DMSO),
and Lp-loaded and THC treated DCs (LpDC/THC) as in Figure17. Seven to 9
days post-injection, splenocytes were harvested and stimulated in vitro with killed
Lp (107/ml) for 24 hr and cytokines (IL-12p40, IFN-gamma and IL-4) detected in
supernatants by ELISAs (A, B and C). Data represent the mean of 5
experiments +/- SEM. # and * (p <0.05) versus the control DC and Lp/DMSO
group, respectively.
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Figure 19. THC suppression of DC IL-12p40 production mediated loss of
Th1 polarization of Lp-primed CD4+ T cells. Cytokines were measured in 24
hr supernatants of co-cultures containing DCs and either Lp-primed or unprimed
CD4 T cells. Primed T cells were obtained 5 days post-infection from the spleens
of mice infected with a sublethal dose of Lp. (A) IL-12p40 measured in cocultures containing Lp-loaded DCs treated with DMSO or THC (10 µM) (LpDC/
DMSO or LpDC/THC) co-cultured with unprimed CD4 T cells. (B) IL-12p40
measured in co-cultures treated as in panel A and containing primed T cells;
recombinant IL-12p40 was added in increasing amounts. (C) IFN-gamma
measured in co-cultures as in panel B and treated with IL-12p40. Data are
representative of 4 experiments.
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Figure 20. THC suppresses Th1 activation signals. Signals delivered by DCs
are required for Th1 activation (2, 152). THC suppressed Th1 immune response
is associated with THC impaired DC function leading to the insufficiency of
(pointed by dot arrows):
1. Polarizing signals including suppressed IL-12p40 production and Notch ligand
Delta 4 expression;
2. Antigen-specific signal through suppressed MHC class II expression;
3. Co-stimulatory signal as low expression of CD86 and CD40.
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Figure 21. Postulated signaling pathways involved in THC suppression
effect on DCs. Lp infection, through TLRs and activation of NF-kappaB and
p38, leads to DC activation and maturation. THC may suppress these effects via
Gi/PI3K/AKT pathway and subsequent regulatory JNK activation; and PPAR
stimulation to suppress NF-kappaB transactivation. Normal arrow represents
positive regulation; dot arrow represents negative regulation.
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DISCUSSION

DCs are potential targets of cannabinoids

Cannabinoids, such as THC, have been shown to be immunosuppressive
and anti-inflammatory (83) and can polarize adaptive immunity in mice away from
Th1 immunity and toward Th2 immunity (89, 134). Polarization by cannabinoids
has recently been reviewed (87, 158) and Th1 suppression occurs following
treatment with endocannabinoids (112, 139), in drug-treated T cell cultures
stimulated with allogenic DCs (191), following LPS and drug injection into C.
parvum-primed mice (168), and in immune responses to tumor cells (192). In at
least one of these studies (168), cannabinoids were shown to suppress
production of the DC cytokine, IL-12. Because DCs are a primary link between
innate and adaptive immunity, we postulated that DCs might be a target of
cannabinoid action and that suppressing the function of these cells could be a
key event in the drug-induced suppression of Th1 polarization.
Intracellular bacterial pathogens can modulate the host cell intracellular
meilu thus providing an environment supportive of intracellular growth and
survival. Lp, for example, a microbe ubiquitous in the aquatic environments and
the causative agent for Legionnaires’ disease in humans, can replicate within
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eukaryotic host cells such as protozoa and human phagocytic and epithelial cells
(68, 131). It has been demonstrated that T helper cell cytokines such as the type
1 cytokine IFN-γ can activate host cells to control Lp infection and other
intracellular pathogens (25, 91, 130). In vivo experiments have shown that Lp
causes severe infection in IFN-γ-deficient mice and IFN-γ treatment results in
increased clearance of the bacteria from the lungs (166). Suppression of
immunity to Lp in mice has also been reported by our group following injection of
THC along with a decrease in Th1 acivity and associated cytokines such as IFNγ and IL-12 (88). DCs are central in the orchestration of the formation of Th1
immunity from naïve CD4+ by providing multiple signals after pathogen priming.
One set of these signals is provided by members of the IL-12 family shown to
play a pivotal polarizing role in Th1 differentiation (106, 138, 145). IL-12p40
protein, which is a subunit shared by two IL-12 family members, IL-12p70 and IL23, has been shown to be indispensable in Th1 development either by
combining with other subunits or on its own (31, 66, 147, 184).

THC suppressed IL-12p40 production in Lp-infected DCs

DCs are a major cell source of IL-12. These cells can be purified from
various mouse tissues such as spleen and bone marrow and studies with
cultures of these cells have shown that a number of different bacteria induce IL12p40 (79). We speculated that cultured DCs would also produce IL-12 in
response to Lp infection since these bacteria have been shown to increase
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serum levels of IL-12 in infected mice (89). We also wanted to study dendritic
cell cultures in order to see if THC added to the cultures directly suppressed IL12 production by these cells. Initially, we observed (Figure 2) Lp infection of DC
cultures triggered a high level of IL-12p40 production that was significantly
inhibited by THC treatment in a concentration-dependent manner (Figure 3).
Thus, it appears that Lp like other microbes directly induces DCs to produce IL12p40 (79). Also, because DCs are a major source for serum IL-12 levels in
infected animals, the current in vitro results suggest THC is suppressing DC
function resulting in decreased serum IL-12 production in treated animals (89).

THC did not suppress LPS-induced IL-12p40 secretion

The immediate recognition of microbes by the innate immune system
plays a crucial role in host defense (121). This recognition process is based on
the detection of unique pathogen-associated molecular patterns (PAMPs) by
pattern recognition receptors of the host such as TLRs. Activation of TLRs not
only plays a critical role in activation of innate immunity but also in the activation
of adaptive immune responses (120) through the production of IL-12p40 and
other polarizing factors. One of the most commonly studied TLRs is TLR4 and
we found that the TLR4 agonist LPS induced a significant amount of IL-12p40 in
our DC cultures, which is consistent with previous reports (127). However, the
LPS effect was not suppressed by THC as was the case with Lp infection (Figure
4). This finding is not surprising in light of recent studies showing that production
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of IL-12p40 after infection with Lp was inhibited in macrophages from TLR2(-/-)
but not inTLR4(-/-) mice suggesting that TLR2, but not TLR4, is involved in
cytokine production by Lp (5). Archer et al. also reported that TLR2 but not TLR4
is involved in MyD88-dependent responses to Lp infection in mice (7). Besides
TLR2, other TLRs might be stimulated by Lp, such as TLR9, which recognizes
bacterial unmethylated CpG motifs and has been shown to be involved in the IL12 response to Lp (135) and other bacteria such as Brucella abortus (72) and
Mycobacterium tuberculosis (9). Thus, our data suggests that the mechanism of
THC suppression of IL-12p40 does not involve the signaling cascades
associated with all of the TLRs, for example TLR4, but might be associated with
others such as TLR2 and 9.

THC suppressed DC maturation and polarizing molecules

Besides producing polarizing cytokines such as IL-12, DCs also promote
the maturation of T helper cells by the production of helper cell-surface proteins
such as MHC class II and co-stimulatory molecules (79). To further explore the
basis of THC modulation of DC function, we examined THC effects on the
expression of these surface markers. The results showed THC treatment
markedly reduced the expression of MHC class II and the co-stimulatory
molecules CD86 and CD40 (Figure 6 and Table 1). The mechanism for this is
unclear at this time; however, signaling through cannabinoid receptors could be
involved because ligation of similar receptors (i.e., Gi-linked) has been shown to
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modulate DC maturation from human PBMCs (33). In addition to the above
markers, Notch ligand expression on DCs has been reported to be critical for T
cell differentiation and various stimuli have been shown to induce the expression
of either Jagged1 (Th2 polarizing) or Delta4 (Th1 polarizing) (6). Our data
showed mRNAs for Jagged1 and Delta4 were induced in DCs after Lp infection;
however, THC treatment significantly suppressed the expression of the Th1
polarizing Delta4 ligand but had little effect on Jagged1 (Figure 7). These
results, coupled with our other findings that the THC-treated DCs are deficient in
promoting Th1 polarizitation, support the previous conclusion that the Delta
ligands induce Th1 cells (6). The THC effect could involve cannabinoid receptors
because G protein-coupled receptors activated through Gs have been shown to
increase Jagged ligand expression and polarize to Th2 (6); therefore,
cannabinoid receptors, coupled to Gi, might be expected to suppress Delta
ligands and Th1 polarization as seen in our study along with inhibiting IL-12 as
shown by others (95).

THC did not affect Lp survival and apoptosis in DCs

To initiate T helper activation, DCs must in addition to producing cytokines
and co-stimulatory molecules, take up and process the bacteria for pathogenrelated antigen presentation. The cells must also survive the bacterial infection
and we wanted to see if antigen uptake by and survival of DC was also affected
by cannabinoids. In contrast to macrophages, wherein intracellular growth of Lp
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was observed (161), we observed that DCs restricted Lp growth with moderate
killing over time (Figure 8). THC-treated DCs showed a similar restriction and
time course of intracellular infection, suggesting Lp handling was the same in
both groups. THC has been reported to induce apoptosis under certain
conditions in mouse DCs (43) and Lp infection has also been shown to be
apoptotic in macrophages and other cells (3, 53). To see if these treatments
together were adversely affecting DC survival, we examined necrosis and
apoptosis induction. Our results with Annexin V staining (Figure 9) showed that
Lp infection induced limited apoptotic activity in DCs similar to that observed in
other cell types (3, 53). THC treatment did not increase the level of apoptosis
and both treatments had no effect on cell necrosis as measured by propidium
iodide staining (Figure 9). The minimal effect of THC on apoptosis we observed
is at variance with that observed previously. We used the drug at 10 µM and this
concentration was shown previously to induce Annexin V positivity in 80% of the
cells (43). However, the previous studies were done using serum-free medium
while ours were done with medium containing fetal calf serum which is known to
reduce the potency (and toxicity) of the added cannabinoids (90). From these
results, it is concluded that THC treatment is not suppressing T helper
polarization by either altering the intracellular life cycle of Lp or by causing
enhanced apoptosis and death of the DCs.
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The involvement of cannabinoid receptors and MAP kinases in THC
effect

The previous studies showed that cannabinoid treatment of DCs altered
the polarizing phenotype of the cells in terms of cytokine and co-stimulatory
production. To uncover the mechanism of these effects, we wanted to see if
cannabinoid receptors might be involved. One previouos report showed that CB1
and CB2 mRNA and protein were expressed in human blood-derived DCs but the
function of these receptors was not studied (113). In the current study, we
showed mRNA for both receptors was also expressed in mouse bone marrowderived DCs and that CB2 message appeared to be more abundant than CB1 in
these cells (Figure 10). Furthermore, using DCs from receptor knockout mice as
well as using CB1 and CB2 antagonists, we observed that these receptors
mediated suppression but only at the lowerTHC concentrations used in these
studies (Figure 12 and Table 2). CB1 and CB2 are Gi protein-coupled receptors
and activate genes by means of the heterotrimeric G protein complex containing
the α-GTP subunit and the βγ dimer (19). Stimulation of cannabinoid receptors
with agonists has been shown to modulate various signaling and transcription
factors; for example, cAMP (164) and AP1 and MAP kinase (50) were decreased
in splenocytes following treatment with cannabinoids, and drug effects were
attenuated by pertussis toxin which inactivates Gi (78). In the current study, we
showed that pertussis toxin treatment completely attenuated the effect of low
THC concentrations; however, complete attenuation could not be achieved at
75

higher drug concentrations (Figure 11). This finding along with the partial
attenuation observed with cells from receptor knockout mice treated with receptor
antagonists suggested that, at the low concentration of THC, the drug is
suppressing cytokine production through activation of a Gi-coupled mechanism
linked to both cannabinoid receptor and non-receptor pathways. The Gi-coupled
mechanism might involve the βγ dimer of the Gi that is reported to suppress IL-12
through MAP kinases (19, 52). Many studies have shown cannabinoids
modulate the activation of MAP kinases (38). These protein kinases are widely
used throughout evolution in many physiological processes and are involved in
all aspects of immune responses, including the regulation of naïve Th cells
differentiation into Th1 or Th2 cells (167) and the production of IL-12 either
directly or indirectly through production of Th2 type cytokines (103, 179, 189).
MAP kinase activation and IL-12 production have been shown to be induced by
G protein-coupled receptors in response to ligands such as bacterial toxins,
neuropeptides and chemoattractants (19). Our data showed that p38 MAP
kinase, but not Erk or JNK, was involved in IL-12p40 production upon Lp
infection (Figure 14). Furthemore, THC treatment enhanced p38 phosphorylation
initially followed by suppression with time (Figure 15). Recently, using human
monocytes, MAP kinase phosphorylation was observed to accompany the
inhibition of LPS/IFN -induced IL-12 production by the mediator C5a and this
was shown to involve the PI3K/Akt signaling pathway (95). Together, these data
suggest THC and other Gi ligands suppress IL-12 through MAP kinase
phosphorylation.
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TRPV1 was not involved in THC effect

Besides cannabinoid receptors, our data suggest that THC might also be
working through other moieties (CBRX?) with affinity for THC but a relatively low
sensitivity to cannabinoid receptor antagonist. For example, it has been reported
that a non-CB1 G protein-coupled receptor in mouse brain was activated by AEA
and WIN55212-2 but not other cannabinoid receptor agonists and was relatively
insensitive to antagonism with SR141716A (20). In addition, the attenuating
activity of SR141716A on the antinociceptive effect of cannabinoids in mice was
found to be receptor agonist-dependent (185), being most potent following
CP55,940 injection and least potent following AEA injection. Vanilloid receptors,
such as TRPV1, might also be involved because they respond to
endocannabinoid treatment but are relatively insensitive to SR141716A (96, 180,
196). There are no previous reports of TRPV1 expression in DCs and we are the
first to show in the current study that DCs readily express TRPV1 mRNA (Figure
10). Because we could find no reports that THC activates TRPV1 receptors on
immune cells, we tested the possibility that TRPV1 was mediating the
suppression of IL-12p40 in our system. DCs, pretreated with the selective
TRPV1 antagonist, capsazepine, were still completely suppressed by THC
treatment suggesting that TRPV1 was not involved in the drug effect on IL-12p40
production (Figure 13).
The above results show that Lp infection of bone marrow-derived DCs
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leads to an increase in IL-12p40 and that co-treatment with THC significantly
suppresses this effect. We also showed that inhibition of Gi signaling completely
attenuates the THC effect at low cannabinoid concentrations; however, inhibiting
CB1 and CB2 at low doses only partially attenuates the THC effect and inhibition
of TRPV1 has no effect. These data suggest that THC is working through Gi
signaling in DCs to suppress IL-12p40 and is also working partially through
cannabinoid receptors in addition to possibly a third receptor with sensitivity to
the effects of THC but low sensitivity to the action of SR compounds. In addition,
we found that besides THC, two endocannabinoids, 2-AG and Virodhamine had
a significant suppression effect on IL-12p40 production from Lp-DCs (Figure 5)
suggesting the possible involvement of endocannabinoids in host antiinflammatory responses. Other cannabinoids, either endogenous or synthetic,
however, did not seem to have significant effect on DC IL-12p40 production.
These observations support the speculation that other targets besides CB1 and
CB2 may exist and that other signaling mechanisms may be involved in different
cannabinoid-mediated actions.

THC impaired the immunization potential of Lp-loaded DCs

The results so far show that THC treatment can change the polarizing
phenotype of DCs to one that is non-supportive of Th1 polarization. To further
examine the drug effects and to functionally test the polarizing potential of the
DCs, we utilized a cellular immune reconstitution model of infection with Lp. DCs
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are potent antigen-presenting cells and loading them with microbial antigens has
been shown to immunize mice against infection with various pathogens (104,
171, 181). In the current study, we showed that DCs loaded in vitro with Lp and
injected into mice immunized and protected the mice to a subsequent lethal Lp
infection (Figure 16). Evidence of immunity to Lp was documented because the
number of CFUs in the spleens of the animals was reduced after injection with
Lp-loaded DCs (Figure 17). Thus, it appears, that bone marrow-derived DCs
have good immunizing potential when loaded or infected with Lp in culture and
then injected into recipient mice. The immunity generated was probably Th1
because replication of Lp in the mice is known to depend on the activity of these
helper cells (134). The next question involved what effect THC treatment had on
the immunizing potential of the loaded DCs. These results showed that THC
treatment attenuated the DC function as evidenced by the reduced ability to
protect against infection and to reduce the number of CFUs in the spleens of
infected mice (Figure 16 and 17).

THC inhibited Th1 activity induced by Lp-loaded DCs

The above results suggested that THC treatment suppressed the Th1
polarizing potential of Lp-loaded DCs. To test this more directly, splenocytes
from immunized mice were analyzed for Th1 and Th2 cytokine production in vitro
in response to Lp antigens. The results in Figure 18 showed that, as expected,
immunization with Lp loaded DCs (LpDC/DMSO group) caused an increase in
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the Th1 polarizing cytokines IL-12p40 and IFN-γ, probably produced by the
antigen-presenting cells and lymphocytes in the splenocyte cultures; however,
this effect was attenuated in splenocytes from animals immunized with THCtreated DCs (LpDC/THC group), suggesting drug treatment suppressed their
polarizing potential. The mechanism surrounding the regulation of Th1 activity is
controversial. IL-4, a key cytokine in promoting Th2 cells (173), was originally
proposed to also inhibit Th1 development; however, more recently this has been
challenged and IL-4 has been shown to actually promote Th1 development by
inducing DCs to produce IL-12 (15). Because of these uncertainties and
because we had previously observed a decrease in IL-12 and increase in IL-4
production in THC-treated and Lp-infected mice (89), we examined for IL-4
production by splenocytes from immunized mice. Figure 18 shows that
immunization suppressed IL-4 production; furthermore, immunization with THCtreated cells had no effect on this suppression. These findings suggest several
things. First, as expected, immunization by Lp led to a decrease in IL-4
producing splenocytes as confirmation of Th1 polarization in response to this
agent (134). Second, it appears that immunization with drug-treated and Lploaded DCs, causes a decrease in Th1 activity with no concomitant increase in
Th2 activity, at least as measured by IL-4 producing splenocytes. Third, these
results would appear to be at odds with our previous finding that THC injection
along with Lp infection led to an increase in IL-4. However, there are a several
differences in the two models and the increase in IL-4 observed in our previous
study (89) occurred within hours after infection and was transient in nature
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whereas, in the current study, IL-4 was measured in splenocytes taken 7 - 9 days
following immunization. Also, in the previous study, THC was injected into Lpinfected mice, whereas in the current model, mice were immunized with THCtreated and Lp-loaded DCs. It is perhaps not surprising that IL-4 production is
regulated differently under these varying conditions of THC administration;
furthermore, the studies suggest that Lp immunization under these conditions
results in primarily a Th1 response and that the suppression of this response by
THC is mediated by mechanisms independent of IL-4 production.

THC suppression of DC IL-12p40 production mediated loss of Th1
polarization

The previous studies suggested that THC treatment of DCs suppressed
their Th1 polarizing function and we wanted to test this directly using an in vitro
co-cultivation paradigm. Because IL-12 is potent in directing Th1 cell
differentiation (109) and because we found that THC suppressed this cytokine in
Lp-infected DC cultures, we evaluated the Th1 promoting potential (as measured
by IFN-γ production) of both Lp-loaded DCs and drug-treated DCs in co-culture
with Lp-primed CD4 T cells as well as the role of IL-12p40 in the response. The
data showed that co-culturing Lp-loaded DCs with Lp-primed T cells led to
enhanced IL-12p40 and IFN-γ production compared to co-culture with unprimed
T cells, and that THC treatment of the DCs attenuated the production of
polarizing cytokines (Figure 19). Furthermore, the addition of exogenous IL81

12p40 to the THC-treated cultures restored the robust production of both IL12p40 and IFN-γ, suggesting that drug suppression of the p40 protein was
responsible for inhibiting Th1 polarization in the cultures. IL-12p70 and IL-23
have also been shown to polarize toward Th1 (75), but drug effects on these
cytokines were not involved because they could not be detected in the
supernatants (data not shown). In addition, IL-10 has been shown to suppress
Th1 polarization under various conditions (187), but again it was not detected in
the supernatants so was probably not involved in the drug effect. These results
show that IL-12p40 can be a major Th1 polarizing protein and that its
suppression by THC is a key factor in the drug-induced inhibition of Th1 cell
development. In this regard, several other reports have shown that the p40
protein has Th1 polarizing potential and affinity for IL-12 receptors (22, 31, 66).
In conclusion, our results show that a major cellular target of THC-induced
immune suppression of Th1 immunity is the dendritic cell and that the drug
attenuates polarizing function by suppressing IL-12p40 production and the
expression of MHC class II, co-stimulatory molecules and Notch ligand Delta4
(Figure 20). Although, THC might compromise the host’s ability to fight infection
it also might be of use in the treatment of chronic inflammatory diseases such as
coeliac disease and Crohn's disease (63, 153), rheumatoid arthritis (177, 182)
and systemic lupus (62). The data reported here suggest that THC and other
cannabinoids may belong to this group of anti-inflammatory drugs.
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SUMMARY

The legalization of marijuana has been debated for years because many
people consider it a relatively benign substance with possible beneficial
medicinal properties. Indeed, it is not as addictive as are other drugs such as
heroin, cocaine or nicotine (122). However, in the aspect of health impact, the
potential risks and benefits of marijuana use remain to be further explored. The
current study investigated the role of cannabinoids in the immune system and
found multiple effects of THC on the cellular immune function of DCs.
Based on the data presented in this study, it appears that during Lp
infection, immature DCs are capable of capturing Lp and its associated antigen.
This leads to maturation and activation of DCs with up-regulation of MHC class II
and other costimulatory molecules and the production of proinflammatory
cytokines. Secretion of IL-12p40 by DCs plays a critical role in activation and
differentiation of Th1 cells which are required for control and elimination of
infection; activation of macrophages and B cells and the production of pathogen
specific neutralizing antibodies such as IgG2a, which also contribute to host
resistance and clearing of the infection. THC, however, suppresses IL-12p40
production in DCs after Lp infection and down-regulates DC MHC class II and
several costimulatory molecules including CD86, CD40 and Notch ligand, leading
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to the depressed Th1 development and immunosuppression against Lp
challenge.
Current data suggest the involvement of Gi signaling and cannabinoid
receptors in THC suppression of IL-12p40 and probably also MHC (67) and
costimulatory molecules. The mechanism may involve the activation of
phosphatidylinositol 3-kinase-protein 3 kinase B/Akt pathway and its downstream
MAP kinases activation. It was recently reported that inhibition of IL-12 by
ligands for Gi-protein-coupled receptors was mediated by the activation of
PI3K/Akt signaling and the MAP kinase JNK (95). Gi receptors for THC may also
stimulate Akt and JNK and consequently suppress the activation of NF-kappaB
and p38 required for DC activation and maturation (190) (Figure 21). Our results
also suggest the existence of mechanisms other than Gi signaling. One possible
candidate is PPAR, which belongs to the nuclear receptor superfamily and can
be activated by cannabinoid ligands such as 2-AG (154) and AJA (24). Recent
studies showed that activation of PPARγ or PPARα may help to control
inflammatory responses through inhibiting NF-kappaB transactivation, which is
critical for DC immunostimulatory functions (141, 156, 190) (Figure 21).
Due to their immunomodulation effects, cannabinoids have been recently
used in the treatment of several chronic inflammatory disorders. For example,
diabetes is associated with the autoimmune destruction of pancreatic β cells and
insulin deficiency. Studies show that THC attenuates the severity of disease in
an animal model and is associated with the suppression of IFN-γ, TNF-α and IL12 mRNA expression in pancreatic tissues from mice (99). More recently,
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Steffens et al. reported that oral administration of THC significantly inhibited the
progression of atherosclerosis in a murine model, suggesting a beneficial effect
of cannabinoids in this chronic inflammatory disease of the vessels (157, 170).
Moreover, in a model of multiple sclerosis, an autoimmune inflammatory disease
of the CNS, the cannabinoid, Win55,212, showed suppression of disease
associated with the suppression of T cell proliferation and IFN-γ secretion and
other pro-inflammatory, Th1-type cytokines, such as IL-1β and TNF-α (35). All
of these studies suggest the potential therapeutic uses of cannabinoids. Our
studies reported here address possible cellular mechanisms of cannabinoidinduced suppression of Th1 immunity. By investigating the effect of cannabinoids
on DCs controlling antigen-driven T-cell polarization, our results not only serve to
expand our understanding of cannabinoid effects in the immune system, but also
provide clues to the cellular mechanism involved and therefore offer more
specific targets for future drug development in the treatment of chronic
inflammatory diseases.
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